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Abstract
Background: Established colorectal cancer cell lines subjected to different 5-fluorouracil (5-FU)
treatment protocols are often used as in vitro model systems for investigations of downstream
cellular responses to 5-FU and to generate 5-FU-resistant derivatives for the investigation of
biological mechanisms involved in drug resistance. We subjected HCT116 colon cancer cells to two
different 5-FU treatment protocols in an attempt to generate resistant derivatives: one that
simulated the clinical bolus regimens using clinically-achievable 5-FU levels, the other that utilized
serial passage in the presence of increasing 5-FU concentrations (continuous exposure). HCT116
Bolus3, ContinB, and ContinD, corresponding to independently-derived cell lines generated either
by bolus exposure or continuous exposure, respectively, were characterized for growth- and
apoptosis-associated phenotypes, and gene expression using 8.5 K oligonucleotide microarrays.
Comparative gene expression analyses were done in order to determine if transcriptional profiles
for the respective treatment derivatives were similar or substantially different, and to identify the
signaling and regulatory pathways involved in mediating the downstream response to 5-FU
exposure and possibly involved in development of resistance.
Results: HCT116 ContinB and ContinD cells were respectively 27-fold and >100-fold more
resistant to 5-FU and had reduced apoptotic fractions in response to transient 5-FU challenge
compared to the parental cell line, whereas HCT116 Bolus3 cells were not resistant to 5-FU after
3 cycles of bolus 5-FU treatment and had the same apoptotic response to transient 5-FU challenge
as the parental cell line. However, gene expression levels and expression level changes for all
detected genes in Bolus3 cells were similar to those seen in both the ContinB (strongest
correlation) and ContinD derivatives, as demonstrated by correlation and cluster analyses.
Regulatory pathways having to do with 5-FU metabolism, apoptosis, and DNA repair were among
those that were affected by 5-FU treatment.
Conclusion: All HCT116 derivative cell lines demonstrated similar transcriptional profiles, despite
the facts that they were generated by two different 5-FU exposure protocols and that the bolus
exposure derivative had not become resistant to 5-FU. Selection pressures on HCT116 cells as a
result of 5-FU challenge are thus similar for both treatment protocols.
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Background
5-FU is one of the standard drugs used in chemotherapeu-
tic regimens for metastatic colorectal cancer worldwide,
despite the fact that resistance to 5-FU is a major obstacle
to successful therapy. Elucidation of the complex biologi-
cal mechanisms involved in development of resistance to
5-FU is an essential step towards predicting or overcoming
such resistance. Established colorectal cancer cell lines
subjected to different 5-FU treatment protocols are often
used as in vitro model systems for investigations of down-
stream cellular responses to 5-FU and to generate 5-FU-
resistant derivatives for the study of biological mecha-
nisms involved in selection for drug resistance. We used
the HCT116 colon cancer cell line for investigations of
response to 5-FU and development of resistance because
this cell line induces high and dose-dependent levels of
apoptosis in response to increasing concentrations of 5-
FU and can thus be considered to be sensitive to 5-FU. We
generated treatment-derivative cell lines from parental
HCT116 cells subjected to two different 5-FU treatment
protocols. One protocol simulated the clinical bolus regi-
mens using clinically-achievable 5-FU levels, the other uti-
lized serial passage of HCT116 cells and continuous
exposure to increasing 5-FU concentrations. The latter
method is the more traditional one used to generate drug
resistance, but one drawback is that such protocols often
use higher, potentially clinically-irrelevant drug concen-
trations. The in vitro bolus 5-FU exposure protocol used
was based on a previously-published protocol designed to
simulate clinical bolus regimens in order to generate treat-
ment-derivative cell lines [1]. This was achieved by a step-
wise dilution of medium after 5-FU addition that was
timed to approximate clinical clearance kinetics. It was
assumed that this protocol would generate 5-FU-resistant
derivatives of HCT116 after only three cycles of treatment,
since it was previously shown to do so for two other color-
ectal cell lines, HT29 and HCT8. We thus opted to use
three cycles of bolus treatment and to subsequently char-
acterize the resultant derivative(s) generated regardless of
resistance status at treatment endpoint.
5-FU resistance phenotypes were assessed in the treatment
derivatives generated by both exposure protocols using
growth inhibition and apoptosis assays. We also com-
pared gene expression in the HCT116 treatment-deriva-
tives generated by both 5-FU exposure protocols in order
to determine whether the signaling and regulatory path-
ways involved in mediating the downstream response to
5-FU exposure (and possibly involved in development of
resistance) were similar or substantially different as a
result of differential treatment. Gene expression in the
treatment derivatives and parental cells was detected and
quantified using oligonucleotide microarrays. Microarray
technology facilitates a more complete and inclusive
experimental approach whereby alterations at the tran-
script level can be simultaneously measured for entire
genomes in response to a defined stimulus, e.g. drug treat-
ment [2]. This allows for a more rapid determination of
whether specific signaling and/or regulatory pathways
have in fact been affected in common for all cell lines
examined, or if they are substantially different from one
cell line to another. The results of our investigations dem-
onstrate that there were strong similarities in gene expres-
sion among all the resultant treatment-derivatives despite
the fact that they were generated by two different treat-
ment protocols, and despite the fact that the bolus deriv-
ative, unlike the continuous exposure derivatives, had not
become resistant to 5-FU after three cycles of treatment.
Selection pressures on HCT116 cells as a result of 5-FU
challenge are thus similar for both treatment protocols.
Results
Assessments of growth- and apoptosis-associated 
phenotypes in HCT116 parental and derivative cells
The drug concentration that resulted in a 50% growth
inhibition (GI50) was determined graphically from sig-
moidal dose-response curves of log-transformed dose val-
ues versus cell counts (as percent of control) following 24
hours of continuous drug exposure. These were used to
calculate resistance levels in the treatment-derivatives. The
GI50 values for 5-FU were previously determined to be
0.09 mM for the parental HCT116 line, 2.4 mM for the
ContinB line, and 10.9 mM for the ContinD line, indicat-
ing that the ContinB and ContinD derivatives were respec-
tively 27-fold and >100-fold more resistant to 5-FU than
the sensitive parental HCT116 cell line [3]. Following 3
cycles of bolus treatment, the HCT116 Bolus3 cell line was
evaluated for its 5-FU resistance level compared to the
parental cells. The GI50 concentration for 5-FU for the
HCT116 Bolus3 cell line was determined to be 0.0022
mM, indicating that this derivative had not become resist-
ant to 5-FU after 3 cycles of bolus treatment (plots not
shown). Despite the fact that it had not become resistant,
we proceeded to further characterize Bolus3 cells in order
to gain valuable information about the early cellular
responses to 5-FU.
Transient challenge with several different concentrations
of 5-FU resulted in significantly lower apoptotic fractions
for the ContinB and ContinD derivatives, respectively,
compared to the sensitive parental cells at 24 hours (Fig-
ure 1). The Bolus3 derivative responded to the same 5-FU
concentrations by inducing dose-dependent levels of
apoptosis; the apoptotic fractions at 24 hours were very
similar to those seen in the parental cell line (Figure 1).
Gene expression in the HCT116 derivatives compared to 
the parental line
The raw gene expression data for all of the 8500 probe sets
on the microarrays for each cell line hybridization haveMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/11
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not been presented in this study, but they are available
upon written request. For individual parental HCT116,
Bolus1, Bolus3, ContinB, and ContinD cell line hybridi-
zations, 51%, 53%, 53%, 52%, and 53% of the total
number of genes on the arrays were detected as present,
respectively. Marginal expression was detected for 1–2%
of all genes on the arrays for each cell line. Since the indi-
vidual hybridized arrays were to be compared for gene
expression levels, the scale factors for each hybridized
array when compared to each other had to demonstrate
less than a 3-fold difference, as recommended by Affyme-
trix. The hybridized arrays in the present study met these
criteria. There was excellent agreement between 2 replicate
array hybridizations for the ContinD cell line (r = 0.980,
p = 0.00), and between Affymetrix oligonucleotide micro-
array and RT-PCR assessments of mRNA level changes for
all 4 genes tested (r = 0.940, p = 0.001, data not shown).
Correlation analyses and hierarchical clustering of gene 
expression data
Correlation analyses of raw signal intensity values (gene
expression levels) demonstrated strong correlations
between each pair of cell lines tested (correlation coeffi-
cients typically greater than 0.90), but the strongest corre-
lations were demonstrated between the Bolus3 and
ContinB derivatives, the Bolus3 and Bolus1 derivatives,
Apoptotic response of HCT116 parental and treatment-derivatives to transient 5-FU challenge for 24 hours Figure 1
Apoptotic response of HCT116 parental and treatment-derivatives to transient 5-FU challenge for 24 hours. 5-
FU was continuously present in the media of exponentially-growing cells for 24 hours. Apoptotic fractions were measured 
using the TUNEL assay as outlined in Materials and Methods. % apoptosis refers to the number of TdT-positive cells, i.e., cells 
that have been end-labeled with a biotin-labeled nucleotide and counterstained with a streptavidin-conjugated FITC 
fluorochrome.
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and the ContinD and parental cell lines, indicating that
these pairs of cell lines tended to have the same gene
expression level patterns (Table 1). For example, if one
cell line in a correlated pair of cell lines had an elevated
expression level for a particular gene, the other cell line
tended to have an elevated expression level for the same
gene, and vice versa, if one cell line had a low gene expres-
sion level for a particular gene, the other cell line tended
to have the same. However, the actual signal intensity val-
ues were not exactly the same for each gene in a correlated
pair of cell lines, although in some cases they could be.
Cluster analysis performed for all cell lines using signal
intensity values demonstrated groupings between Con-
tinB and Bolus3, and between ContinD and Bolus1 (Fig-
ure 2). The length of the vertical bars on the cluster plot
indicates the degree of difference in gene expression level
patterns between cell lines, showing that the ContinB/
Bolus3 and ContinD/Bolus1 cell line pairs were more
similar to each other than either of these pairs was to the
parental line for this parameter. ContinB and Bolus3
derivatives and Bolus3 and Bolus1 derivatives were
strongly correlated for the signal log2 ratio parameter,
demonstrating that gene expression changes in the deriv-
ative cells (relative to the parental cells against which they
were compared) were very similar in these pairs of cell
lines. The ContinD derivative demonstrated moderate
correlations with the Bolus3 derivative, with the ContinB
derivative, and with the Bolus1 derivative for the same
parameter (Table 1), indicating that gene expression
changes were more dissimilar in these pairs of cell lines.
The length of the vertical bars on the cluster plot in Figure
3 (cluster analysis for signal log2 ratios) indicates the
degree of difference in gene expression changes between
cell lines, showing that the ContinB/Bolus3 and ContinD/
Cluster diagram showing correlations among all HCT116 cell lines for probe signal intensities (gene expression levels) for all  genes examined Figure 2
Cluster diagram showing correlations among all HCT116 cell lines for probe signal intensities (gene expres-
sion levels) for all genes examined. The pairs of cell lines that are connected tend to have the same gene expression level 
patterns, e.g., elevated gene expression level for one gene in one cell line tends to imply elevated gene expression level in the 
other cell line for the same gene. The length (linkage distance) of the vertical bars on the cluster plot indicates the degree of 
difference in gene expression level patterns between cell lines, e.g., the ContinB/Bolus3 and ContinD/Bolus1 cell line pairs 
were more similar to each other than either of these pairs was to the parental line for this parameter.
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Cluster analysis of signal log2 ratios (gene expression changes) for four derivative cell lines Figure 3
Cluster analysis of signal log2 ratios (gene expression changes) for four derivative cell lines. Similar gene expres-
sion changes are demonstrated in the grouped pairs of treatment-derivatives, varying in degree of difference according the link-
age distance. The smaller the linkage distance, the more similar the gene expression changes. ContinB and Bolus3 derivatives 
had similar gene expression changes, as did ContinD and Bolus1 derivatives.
Table 1: Correlation analyses for signal intensity values (gene expression levels) and signal log2 ratios (gene expression changes) in 
HCT116 derivative and parental cells, using microarray expression data for all genes.
Pair of variables Gene expression levels (r-
values)
Gene expression changes (r-
values)
Bolus3 and Bolus1 0.970 0.603
and ContinB 0.971 0.674
and ContinD 0.957 0.457
and parental 0.947
Bolus1 and ContinB 0.963 0.531
and ContinD 0.963 0.382
and parental 0.959
ContinB and ContinD 0.954 0.428
and parental 0.944
ContinD and parental 0.968
Results of correlation analyses are presented as correlation coefficients (r-values). All correlations were significant, with p-values = 0.00.
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Bolus1 cell line pairs were again more similar to each
other than either of these pairs was to the other pair for
this parameter.
Specific Affymetrix software filters were applied to the
gene expression data to provide information about the
regulatory pathways affected as a result of treatment (e.g.
apoptosis and DNA repair); Table 2 shows some of the
affected regulatory pathways and the corresponding genes
scored as up- or down-regulated in one or all of the
HCT116 treatment-derivatives.
Discussion
We compared gene expression and specific growth- and
apoptosis-associated phenotypes in HCT116 treatment-
derivatives generated either by continuous exposure to 5-
FU or by using an exposure protocol that more directly
simulated the clinical bolus regimens. The aim was to
determine whether the signaling and regulatory pathways
involved in mediating the downstream response to 5-FU
exposure were similar or substantially different as a result
of these two different treatment protocols. A previous
study [1] attempted to systematically address this ques-
tion by determining the activity of different enzymes
involved in 5-FU metabolism in cell lines generated by
these two methods, and demonstrated differences in
enzyme activity levels between the respective resultant
derivatives. However, the authors did not have DNA
microarray technology available to them at that time in
order to gain complete transcriptional profiles of the cell
lines used in their study. Use of this technology in the
present study yielded comparative information about
expression levels simultaneously for the same 8500 genes
for three derivative cell lines and one parental cell line
(baseline) from which the other three were derived, allow-
ing for a more rapid determination of whether specific sig-
naling and/or regulatory pathways had in fact been
affected in common for all derivative cell lines examined,
or if they were substantially different from one cell line to
another.
All derivative cell lines demonstrated similar transcrip-
tional profiles, despite the facts that they were generated
by two different 5-FU exposure protocols and that they
differed substantially in their levels of resistance to 5-FU.
This suggests that similar signaling and regulatory path-
ways were involved in mediating the downstream
response to 5-FU in each of the derivative lines, i.e., that
the selection pressures on the cells in terms of dealing
with 5-FU challenge are similar for both exposure proto-
cols. Despite the fact that use of the in vitro bolus model
for resistance development did not result in 5-FU-resistant
derivatives after 3 cycles of treatment, we opted to proceed
with characterizations of the resultant bolus derivatives
generated. We reasoned that these derivatives could pro-
vide valuable information about the early downstream
responses to 5-FU. The Bolus3 derivative had a transcrip-
tional profile that was very similar to that seen in the
strongly-resistant ContinB derivative. The actual genes
selected for and expressed in response to 5-FU exposure,
and the levels of gene expression were very similar
between the two cell lines; additionally, many of the same
genes were scored as up- or down-regulated in both deriv-
atives. The Bolus3 and Bolus1 derivatives were also
Table 2: Examples of some of the regulatory pathways affected by 5-FU exposure, and associated genes that were scored as up- or down-
regulated in one or more HCT116 treatment-derivatives.
Regulatory pathway 
affected
Altered gene in one or 
more derivatives
Bolus3 signal log2 ratio ContinB signal log2 
ratio
ContinD signal log2 
ratio
5-FU-metabolism DHFR 0.6 0.7 1.0
DPYD -1.0 -1.5 -0.9
DTYMK 1.0 1.4 0.7
TYMS 0.7 0.9 0.7
UP 1.2 1.6 (0.3)
Apoptosis ANXA4 -1.0 -1.2 (-0.3)
BIRC5 0.6 1.2 0.7
BNIP3L -2.4 -2.7 -0.5
IRAK1 1.4 1.6 0.6
MALT1 0.6 1.5 0.8
PDCD4 -2.8 -2.9 (0.0)
DNA repair FANCG 2.1 2.3 1.7
FEN1 1.5 1.7 1.1
RAD23B 2.3 2.3 (0.2)
Signal log2 ratios ≥ 0.5 defined an up-regulated gene, and signal log2 ratios ≤ -0.5 defined a down-regulated gene. Values in parentheses represent 'no 
change' scores and are included here for comparison.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/11
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strongly correlated for gene expression levels and gene
expression level changes, not surprisingly since the Bolus3
derivative is a simply a sequential continuation of the
Bolus1 cell line, differing only in the number of bolus
cycles it has undergone. Gene expression analysis of
Bolus1 cells was included in the study in order to gain val-
uable information about the transcriptional profile asso-
ciated with one cycle of 5-FU treatment and recovery. The
results indicate that already after one round of 5-FU treat-
ment and recovery that these cells had a transcriptional
profile that was very similar to that seen in the Bolus3 and
ContinB cells. The ContinD derivative demonstrated
strong correlations with the ContinB, Bolus3 and Bolus1
derivatives for gene expression levels, but only moderate
correlations with the ContinB, Bolus3 and Bolus1 deriva-
tives for gene expression changes. A strong correlation was
demonstrated with a replicate ContinD sample for gene
expression levels, indicating a high degree of reproducibil-
ity of the data. All HCT116 treatment-derivative lines also
demonstrated gene expression that was very similar to the
parental HCT116 cell line, reflecting their origin from this
cell line. However, the Bolus 3 and ContinB cell lines were
the treatment-derivatives that differed most from the
parental line, yet were most like each other. The ContinD
derivative demonstrated the strongest correlation with the
parental HCT116 cell line with regard to gene expression
levels of all the derivatives, followed by the Bolus1 deriv-
ative, thus the ContinD derivative is most like the parental
line. This was also demonstrated by cluster analysis using
gene expression level data for all cell lines. The ContinD
line clustered together with the Bolus1 line, whereas the
ContinB and Bolus3 lines clustered together; the parental
HCT116 cell line clustered together with each of these
individual clusters, but was much closer distance-wise to
the ContinD/Bolus1 cluster. Further analysis of the gene
expression data for all of the HCT116 treatment-deriva-
tives, with specific focus on the differences in gene expres-
sion between these cell lines, will lead to an explanation
of what defines resistance to 5-FU in these cells. We con-
clude that the ContinB and ContinD derivatives can be
useful in vitro models for the study of the molecular mech-
anisms underlying 5-FU resistance, whereas the Bolus3
derivative, while not resistant to 5-FU, can be useful for
the study of early cellular responses to 5-FU exposure.
Recent articles about resistance to anticancer agents have
discussed the importance of drug target alterations, DNA
repair, and evasion of apoptosis as relevant mechanisms
of drug resistance [4,5]. In the present study, genes on sig-
naling and regulatory pathways associated with 5-FU
metabolism, apoptosis, and DNA repair were among the
many genes shown to be significantly altered during selec-
tion for 5-FU resistance. The main mechanism of action of
5-FU is to inhibit thymidylate synthase, a key enzyme in
the de novo synthesis of dTMP from dUMP [2,6]. Cells
continually exposed to 5-FU must compensate for the
inhibition of thymidylate synthase and deal with the DNA
damage / eventual apoptosis that may result due to FdUTP
misincorporation into DNA. Overexpression of the
thymidylate synthase (TYMS) gene is a characteristic of 5-
FU-resistant cell lines [7,8] and is predictive of poor
response to 5-FU treatment in colorectal cancer [9,10].
The TYMS gene was overexpressed nearly 2-fold in all of
the HCT116 treatment-derivatives in the present study
compared to the parental cells. This suggests that up-regu-
lation of TYMS is one of the first cellular responses to
repeated 5-FU exposure, but that it may not necessarily
define a 'resistance' phenotype, since the Bolus3 deriva-
tive, while not 'resistant' to 5-FU as assessed by growth
inhibition assays, expressed levels of this gene similar to
those seen in the strongly-resistant ContinB and ContinD
derivatives. Several other genes involved in 5-FU metabo-
lism (e.g. DTYMK, UP, DHFR) were also up-regulated in
both the Bolus3 derivative and in one or both of the con-
tinuous derivatives, suggesting that their overexpression
contributes to but may not necessarily define a 'resistance'
phenotype.
Since we have a documented reduced apoptosis pheno-
type for the ContinB and ContinD derivatives (but not for
the Bolus3 derivative), we conclude that loss of sensitivity
to apoptosis induction accompanies selection for resist-
ance to 5-FU in these cell lines. This phenotype cannot be
explained by loss of wild-type p53 function, since both
the ContinB and ContinD cell lines retained a wild-type
TP53  genotype [3], and both cell lines induce p53 in
response to transient 5-FU challenge in similar fashion to
the parental cell line. It was thus relevant to examine
expression levels of other genes involved in the regulation
of apoptosis. Genes involved in apoptosis promotion,
e.g., ANXA4, BNIP3L, and PDCD4, were strongly down-
regulated in the ContinB and Bolus3 derivatives (but not
in the ContinD derivative) in the present study. Genes
involved in apoptosis inhibition, e.g. BIRC5 and MALT1,
were strongly up-regulated in the ContinB derivative but
not in the Bolus3 or ContinD derivatives, whereas IRAK1
was strongly up-regulated in both the ContinB and Bolus3
derivatives, but not in the ContinD derivative. Overex-
pression of BIRC5, MALT1, and IRAK1 may thus contrib-
ute to the reduced apoptosis phenotype in the ContinB
derivative cell line, but other (still unknown) apoptotic-
regulatory genes might account for the same in the Con-
tinD derivative. Overall, our results are consistent with
recent publications that suggest that overexpression of
apoptosis-inhibitory genes or underexpression of
apoptosis-promoting genes contribute to a drug resistance
phenotype [4,5], at least for the ContinB derivative.
Likewise, DNA repair genes such as FEN1 and FANCG
were overexpressed in both continuous-treatmentMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/11
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derivatives, suggesting that the latter can repair DNA more
effectively than the parental line, consistent with recent
studies that suggest that DNA repair contributes to general
drug resistance [4,5]. It is unknown at present whether
overexpression of these genes results in more efficient
DNA repair since we have not measured DNA repair activ-
ity. The ContinB derivative also overexpressed RAD23B.
The Bolus3 cell line also overexpressed all three of these
DNA repair genes at levels similar to those measured for
the continuous derivatives, despite its lack of resistance to
5-FU. An investigation of what underlies the strong 5-FU
resistance demonstrated in the ContinB and ContinD
cells must therefore focus on other highly-up-regulated or
down-regulated genes and their levels of expression, as
well as on the alterations that have occurred at the gene
level (e.g. increase in copy number). These will involve
both functional studies using gene silencing and the use
of genomic arrays, respectively, and this work is currently
underway in our laboratory.
The bolus exposure regimen employed in the present
study was previously shown to generate resistant cell pop-
ulations after only 3 cycles of treatment in two different
colorectal cancer cell lines, HCT8 and HT29 [1], but this
was not the result for the HCT116 cells used in our study.
One probable explanation for this is that HCT116 cells
may be more difficult to make resistant to 5-FU than
HCT8 and HT29 cells, and that it would take exposure to
higher concentrations of the drug or to increased numbers
of treatment cycles in order to achieve resistance. The fact
that HCT116 cells are DNA-mismatch repair-deficient due
to lack of hMHL1 expression may explain their tolerance
to 5-FU, since loss of DNA mismatch repair has been
shown to confer resistance to 5-FU [11,12]. It has been
shown that lack of hMHL1 expression is the result of
hypermethylation of the hMHL1 gene, and a recent pub-
lication demonstrated that it was possible to restore sensi-
tivity to 5-FU (in effect, overcome in vitro resistance) by re-
expression of hMHL1 protein through demethylation in
hypermethylated cell lines [13]. We have not assessed the
methylation status of this gene in any of the cell lines used
in this study.
Conclusions
The present study demonstrates that downstream signal-
ing and regulatory pathways affected by continuous 5-FU
exposure were similar to those affected by clinically-rele-
vant 5-FU exposure, i.e., that HCT116 treatment-deriva-
tives generated by two different 5-FU exposure protocols
have similar transcriptional profiles. The selection pres-
sures on HCT116 cells as a result of 5-FU challenge can
thus be considered to be similar for both types of treat-
ment protocols. HCT116 treatment-derivatives generated
by continuous exposure to 5-FU can be useful in vitro
models for the study of the molecular mechanisms under-
lying 5-FU resistance because they provide information
about the types of signaling and regulatory pathways
affected by repeated exposure to 5-FU. The HCT116
Bolus3 derivative, while not resistant to 5-FU, can be use-
ful for the study of early cellular responses to 5-FU expo-
sure. The specific differences between these derivatives in
terms of the types of genes expressed and the expression
levels of these genes will aid in the elucidation of factors
that define resistance to 5-FU. Finally, the stability of the
resistance phenotypes in the strongly-5-FU-resistant Con-
tinB and ContinD cell lines are most likely due to geno-
typic alterations, and future studies will focus on
determining the types of alterations that have occurred at
the gene level through the use of genomic arrays, and the
point during resistance development at which they
occurred.
Methods
Cell lines, culture conditions and chemicals
Early passage HCT116 cells (ATCC CCL 247) derived
from a poorly-differentiated colonic adenocarcinoma
were used. These cells have a wild-type TP53 genotype, a
somatic frameshift mutation in exon 3 of the BAX gene
[14,15], DNA-mismatch repair-deficiency due to lack of
hMHL1 expression [16], two different thymidylate
synthase enzymes [17,18] and a near-diploid DNA com-
plement. Cells were maintained as monolayers in RPMI
1640 supplemented with 10% heat-inactivated fetal calf
serum, 2 mM glutamine and 0.6% Pen-Strep at 37°C in a
5% CO2 atmosphere (all cell culture reagents and plas-
ticware purchased from Invitrogen Gibco). 5-FU was
obtained from Amersham Life Sciences, England.
Serial passage of HCT116 cells in increasing 5-FU 
concentrations (continuous exposure)
Derivative cell lines were generated by serial passage of
parental HCT116 cells in the presence of increasing con-
centrations of 5-FU, and recently characterized for various
phenotypes and genotypes [3]. Briefly, intermittent 5-FU
treatments of exponentially-growing HCT116 cells for 48
hours, followed by recovery periods in drug-free medium
until the cells regained exponential growth (an interval
corresponding to circa 18 doubling times), were used to
generate independent treatment derivatives. The concen-
trations of 5-FU used ranged from 5–770 µM. Two inde-
pendent derivatives, designated ContinB and ContinD
(original designation ResB and ResD; designation
changed for the present study in order to emphasize dif-
ference between derivatives generated by continuous 5-FU
exposure versus those generated by bolus treatment), were
selected and cultured further. Drug treatments continued
until both derivative cell lines demonstrated stable resist-
ance to 5-FU challenge, as assessed by growth inhibition
assays.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/11
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Bolus 5-FU exposure of HCT116 cells (clinical clearance 
kinetics model)
Pizzorno and Handschumacher [1] used 5-FU concentra-
tions that were within the achievable clinical range to treat
two different colon cancer cell lines, using an exposure
protocol that more directly simulated the clinical regi-
mens currently in use. The bolus protocol provided a drug
concentration profile similar to that obtained in patients
after a 600 mg/m2 dose of 5-FU [1]. This was achieved by
a stepwise dilution of medium after 5-FU addition that
was timed to approximate clinical clearance kinetics. The
initial 5-FU concentration of 500 µM was diluted out to
250 µM, 100 µM, 20 µM, 2 µM and finally to 0.5 µM over
the course of approximately 5 hours. Cells were then
allowed to incubate in 0.5 µM 5-FU for 24 hours. The fol-
lowing day, the same regimen was repeated. This protocol
was repeated daily for 5 consecutive days, at which point
the cells were removed to drug-free media via a medium
shift and allowed to recover. The entire regimen was
repeated 3 times at intervals corresponding to about 18
doubling times [1]. We performed 3 cycles of treatment
since these authors demonstrated that their exposure reg-
imen resulted in the selection of (transiently)-resistant
cell populations after only three cycles of treatment in two
other colorectal cancer cell lines, HCT8 and HT29. Cell
cultures that had recovered following each treatment cycle
were frozen down for subsequent gene expression and
growth inhibition analyses; these were labeled as HCT116
Bolus1, Bolus2, and Bolus3. Assessments of growth inhi-
bition were done only for HCT116 Bolus3, since this
derivative should in principle have developed the most
resistance to 5-FU after three cycles of treatment. Gene
expression levels were quantified for both HCT116
Bolus3 and Bolus1 cells; gene expression in the latter was
used as a basis for comparison with the same in HCT116
Bolus3 cells. Untreated exponentially-growing parental
HCT116 cells were used as controls.
Subsequent characterizations of all HCT116 derivative
cell lines were done on exponentially-growing cells that
had been grown without 5-FU in the media for at least one
month, taking into account recommendations for in vitro
resistance work presented in a recent review [2].
Assessment of resistance levels in HCT116 parental and 
treatment-derivative cell lines using growth inhibition 
assays
HCT116 parental and treatment-derivative cells that were
maintained in regular medium without 5-FU were seeded
in duplicate in 12-well plates and allowed to grow until
they reached early exponential growth. Media was shifted
24 hours before the addition of 5-FU. Exponentially grow-
ing cells were incubated in the absence or presence of 8–
10 different 5-FU concentrations for 24 hours, at which
time the medium was aspirated off, the cells trypsinized
and counted using a trypan blue viability assay. The drug
concentration that resulted in a 50% growth inhibition
(GI50) was determined graphically from sigmoidal dose-
response curves of log-transformed dose values versus cell
counts (percent of control) at 24 hours of continuous
drug exposure. The resistance level was calculated as the
ratio between the GI50 concentrations of the drug in the
growth medium of the resistant and the sensitive cells,
respectively. Two replicate experiments were performed.
Quantification of apoptotic response to 5-FU in HCT116 
parental and treatment-derivative cell lines
Apoptotic response to transient 5-FU challenge was quan-
tified in the parental and treatment-derivative HCT116
cell lines at 24 hours following 5-FU addition to the
medium, using the TUNEL method for apoptosis detec-
tion. Different concentrations of 5-FU were added to the
medium of exponentially-growing cells that had other-
wise been maintained in 5-FU-free medium for one
month. Apoptotic cells in control and treated samples
were identified by end-labeling apoptotic DNA fragments
with a fluorescent marker (streptavidin-FITC labeling of
incorporated biotin-conjugated dUTP), mediated by ter-
minal deoxynucleotidyl transferase (TdT) [19]. Cells were
counterstained with 5 µg/ml propidium iodide to stain
cellular DNA. The resulting labeled apoptotic fractions
were quantified in the control and treated cell samples
using a FACSCalibur laser flow cytometer (BDIS, San Jose,
CA), after appropriate gating using pulse-width analysis of
the DNA content signal to exclude doublets and aggre-
gates. Two replicate experiments were performed.
Oligonucleotide array analyses and quantification of gene 
expression levels
Harvesting of the cells for RNA extraction for comparative
investigations of gene expression in the treatment-deriva-
tive and parental HCT116 cell lines was done on exponen-
tially growing cells that were maintained in regular
medium without 5-FU at the time of the actual microarray
investigations. Analyses were done using Gene Chip
Human Genome 8.5 K Focus Arrays (Affymetrix, Santa
Clara, CA). Information about these arrays can be found
at http://www.affymetrix.com. RNA isolation, target labe-
ling and hybridization to the arrays, array washing, stain-
ing, scanning and data analysis were performed using
Affymetrix standard protocols, instrumentation, and
Microarray Suite version 5.0 software. One replicate
hybridization was performed for the ContinD derivative
(same RNA sample, labeled anew and hybridized) in
order to confirm the reproducibility of gene expression
alterations between two same sample hybridizations.
The Microarray Suite software contains Detection, Signal,
Change, and Signal log ratio algorithms that are used to
evaluate individual gene expression for all gene probe setsMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/11
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(including controls) on the microarrays. These algorithms
are described in detail in the Statistical Algorithms Descrip-
tion Document published by Affymetrix and available on
their website. Briefly, the Detection algorithm assesses
probe pair saturation, calculates a detection p-value, and
assigns a present (P), marginal (M), or absent (A) call. The
Signal algorithm calculates a quantitative metric for each
probe set using the stray and real signal hybridization
intensities, corresponding to Mismatch (MM) and Perfect
Match (PM) minus MM, respectively. For comparison
analysis of two samples (in the present study, a treatment
derivative versus the parental cell line), a Change algo-
rithm is used to generate a change p-value and an associ-
ated 'change', which indicates whether gene expression is
increased (I), marginally-increased (MI), decreased (D),
marginally-decreased (MD) or no change (NC) in a resist-
ant derivative compared to the parental cell line. The Sig-
nal log ratio algorithm produces a quantitative estimate of
these gene expression changes in the form of signal log2
ratios.
Correlation and cluster analyses for HCT116 derivative
and parental cell lines were done for the following param-
eters: a) raw signal intensity values: these values are actual
gene expression levels, and were compared for all genes in
all cell lines (derivatives and parental) using Spearman
correlation analysis; b) signal log2 ratios: these values are
quantitative estimates of gene expression changes, and
were compared using Spearman correlation analysis.
Hierarchical cluster analyses for the same parameters were
done using the Joining:Tree clustering method, Complete
linkage, distance metric was Euclidean distances.
Real-time RT-PCR
Alterations of gene expression detected using Gene Chip
arrays were confirmed by real-time RT-PCR for 4 genes,
TYMS, F3, FEN1, and TOP2A, in ContinB and ContinD
cells. These genes were chosen for RT-PCR analysis
because they were shown to be strongly up- or down-reg-
ulated by microarray analysis in ContinB and/or ContinD
cells [3]. The GAPDH gene was used as an internal control.
Information about the cDNA-specific primers and proce-
dure used for these investigations are available in the
same study.
Statistical analyses
Correlation and hierarchical cluster analyses were per-
formed using Statistica version 5.5 software (StatSoft Inc.,
Tulsa, OK). p-values ≤ 0.05 were considered to denote sta-
tistical significance.
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